Amgen Inc. has announced the rapid acceleration of its clinical trial program for obesity, marking it as one of the largest in the company's 45-year history. The investigational medicine, maridebart cafraglutide, also known as MariTide, is at the center of the Phase 3 MARITIME program. This program aims to evaluate the safety and efficacy of MariTide for the treatment of obesity and obesity-related conditions. The MARITIME program includes MARITIME-1, a study focused on individuals with overweight or obesity, and MARITIME-2, which targets those living with type 2 diabetes and overweight or obesity. The results of these trials have not yet been presented. Further updates and information about the Phase 3 clinical program can be accessed through the MARITIME website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。